Lohith Gowda, MD, MRCP

• Alexa Siddon
• Alexander B. Pine
• Alfred Lee
• Allen Bale
• Alyssa Ann Grimshaw
• Amer Zeidan
• Ami Rubinowitz
• Amy Ogurick
• Daniel Zelterman
• David A. Hafler
• Erin Longbrake
• Francine Foss
• Giulia Biancon
• Howard Forman
• Iris Isufi
• Jeanne Hendrickson
• Jennifer M. Kwan
• Jennifer VanOudenhove
• Kenneth B. Roberts
• Kunal Potnis
• Lynn D. Wilson
• Manoj M Pillai
• Maricar Malinis
• Marwan Mikheal Azar
• Mary Tomayko
• Michael Girardi
• Mina Xu
• Natalia Neparidze
• Niketa C Shah
• Nikolai Podoltsev
• Noffar Bar
• Po-Han Chen
• Ronald George Hauser
• Rong Fan
• Rory Shallis
• Scott Huntington
• Shalin Kothari
• Shana Gleeson
• Sheela Shenoi
• Stephanie Halene
• Stuart Seropian
• Tarsheen Sethi
• Terri Parker
• Wade Schulz

Anemia, Aplastic; Blood Transfusion; Bone Marrow Diseases; Immunotherapy; Leukemia; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Hematopoietic Stem Cell Transplantation; Primary Myelofibrosis

• Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center ExperienceHamouche R, Foss F, Mirza S, Di M, Isufi I, Bar N, Gowda L, Perreault S, Roberts K, Seropian S, Sethi T. Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience. Blood 2023, 142: 2172. DOI: 10.1182/blood-2023-189414.
• Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection (Small Methods 10/2023)Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection (Small Methods 10/2023). Small Methods 2023, 7 DOI: 10.1002/smtd.202370057.
• P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19‐CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCELRasheed Y, Mirza A, Pine A, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, Vanoudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19‐CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCEL. HemaSphere 2023, 7: e19857ae. PMCID: PMC10430478, DOI: 10.1097/01.hs9.0000972428.19857.ae.
• P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCELMirza A, Pine A, Hamouche R, Rasheed Y, Leveille E, Goshua G, Gu S, Liu Y, Vanoudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL. HemaSphere 2023, 7: e1847498. PMCID: PMC10430598, DOI: 10.1097/01.hs9.0000972412.18474.98.
• Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysisRagon B, Shah M, D’Souza A, Estrada-Merly N, Gowda L, George G, de Lima M, Hashmi S, Kharfan-Dabaja M, Majhail N, Banerjee R, Saad A, Hildebrandt G, Mian H, Abid M, Battiwalla M, Lekakis L, Patel S, Murthy H, Nieto Y, Strouse C, Badawy S, Hadidi S, Dholaria B, Aljurf M, Vesole D, Lee C, Pawarode A, Gergis U, Miller K, Holmberg L, Afrough A, Solh M, Munshi P, Nishihori T, Anderson L, Wirk B, Kaur G, Qazilbash M, Shah N, Kumar S, Usmani S. Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Advances 2023, 7: 2746-2757. PMID: 36827681, PMCID: PMC10275699, DOI: 10.1182/bloodadvances.2022009138.
• Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine ProtectionKim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection. Small Methods 2023, 7: e2300594. PMID: 37312418, PMCID: PMC10592458, DOI: 10.1002/smtd.202300594.
• Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patientsBoyiadzis M, Zhang M, Chen K, Abdel-Azim H, Abid M, Aljurf M, Bacher U, Badar T, Badawy S, Battiwalla M, Bejanyan N, Bhatt V, Brown V, Castillo P, Cerny J, Copelan E, Craddock C, Dholaria B, Perez M, Ebens C, Gale R, Ganguly S, Gowda L, Grunwald M, Hashmi S, Hildebrandt G, Iqbal M, Jamy O, Kharfan-Dabaja M, Khera N, Lazarus H, Lin R, Modi D, Nathan S, Nishihori T, Patel S, Pawarode A, Saber W, Sharma A, Solh M, Wagner J, Wang T, Williams K, Winestone L, Wirk B, Zeidan A, Hourigan C, Litzow M, Kebriaei P, de Lima M, Page K, Weisdorf D. Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients. Leukemia 2023, 37: 1173-1173. PMID: 36949156, DOI: 10.1038/s41375-023-01814-2.
• Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphomaPotnis K, Di M, Isufi I, Gowda L, Seropian S, Foss F, Forman H, Huntington S. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma. Blood Advances 2023, 7: 801-810. PMID: 36342852, PMCID: PMC10011202, DOI: 10.1182/bloodadvances.2022008097.
• 513 Outcomes after Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplant in Patients with Mature T Cell Lymphomas Based on Disease Status at Transplant: A Single Institution ExperienceMirza A, Hamouche R, Di M, Isufi I, Bar N, Sethi T, Gowda L, Perreault S, Roberts K, Seropian S, Foss F. 513 Outcomes after Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplant in Patients with Mature T Cell Lymphomas Based on Disease Status at Transplant: A Single Institution Experience. Transplantation And Cellular Therapy 2023, 29: s383-s384. DOI: 10.1016/s2666-6367(23)00581-x.
• 517 Outcomes after Reduced-Intensity Conditioning with Pentostatin and Low-Dose TBI in Patients with T Cell Prolymphocytic Leukemia (T-PLL): A Single Institution ExperienceHamouche R, Mirza A, Di M, Isufi I, Bar N, Sethi T, Gowda L, Perreault S, Roberts K, Seropian S, Foss F. 517 Outcomes after Reduced-Intensity Conditioning with Pentostatin and Low-Dose TBI in Patients with T Cell Prolymphocytic Leukemia (T-PLL): A Single Institution Experience. Transplantation And Cellular Therapy 2023, 29: s387-s388. DOI: 10.1016/s2666-6367(23)00585-7.
• 523 Allogeneic Transplantation for Rare Subtypes of T-Cell Lymphoma: Outcomes with a Pentostatin/Low-Dose Total Body Irradiation RegimenDi M, Mirza A, Hamouche R, Isufi I, Bar N, Sethi T, Gowda L, Perreault S, Roberts K, Seropian S, Foss F. 523 Allogeneic Transplantation for Rare Subtypes of T-Cell Lymphoma: Outcomes with a Pentostatin/Low-Dose Total Body Irradiation Regimen. Transplantation And Cellular Therapy 2023, 29: s392. DOI: 10.1016/s2666-6367(23)00591-2.
• Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemiaMurthy S, Logan B, Bo‐Subait S, Beitinjaneh A, Devine S, Farhadfar N, Gowda L, Hashmi S, Lazarus H, Nathan S, Sharma A, Yared J, Stefanski H, Pulsipher M, Hsu J, Switzer G, Panch S, Shaw B. Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia. American Journal Of Hematology 2023, 98: 608-619. PMID: 36606713, PMCID: PMC10290878, DOI: 10.1002/ajh.26834.
• Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene VicleucelMirza A, Pine A, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, VanOudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel. Blood 2022, 140: 10410-10412. DOI: 10.1182/blood-2022-168374.
• Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)Mirza A, Hosing C, Foss F, Kim S, Moskop A, Oloyede T, Ahmed S, Hematti P, Turtle C, Pasquini M, Gowda L. Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR). Blood 2022, 140: 4633-4635. DOI: 10.1182/blood-2022-163750.
• Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patientsBoyiadzis M, Zhang M, Chen K, Abdel-Azim H, Abid M, Aljurf M, Bacher U, Badar T, Badawy S, Battiwalla M, Bejanyan N, Bhatt V, Brown V, Castillo P, Cerny J, Copelan E, Craddock C, Dholaria B, Perez M, Ebens C, Gale R, Ganguly S, Gowda L, Grunwald M, Hashmi S, Hildebrandt G, Iqbal M, Jamy O, Kharfan-Dabaja M, Khera N, Lazarus H, Lin R, Modi D, Nathan S, Nishihori T, Patel S, Pawarode A, Saber W, Sharma A, Solh M, Wagner J, Wang T, Williams K, Winestone L, Wirk B, Zeidan A, Hourigan C, Litzow M, Kebriaei P, de Lima M, Page K, Weisdorf D. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients. Leukemia 2022, 37: 1006-1017. PMID: 36310182, PMCID: PMC10148918, DOI: 10.1038/s41375-022-01738-3.
• Esophageal Graft-vs-Host Disease Presenting as Esophagitis Dissecans SuperficialisOgurick A, Liu C, Gowda L, Li D. Esophageal Graft-vs-Host Disease Presenting as Esophagitis Dissecans Superficialis. ACG Case Reports Journal 2022, 9: e00833. DOI: 10.14309/crj.0000000000000833.
• Impact of second primary malignancy post-autologous hematopoietic stem cell transplantation on outcomes of multiple myeloma: A CIBMTR analysis.Ragon B, D'Souza A, Estrada-Merly N, Fraser R, George G, Gowda L, Shah N, Qazilbash M, Kumar S, Horowitz M, Usmani S, Shah M. Impact of second primary malignancy post-autologous hematopoietic stem cell transplantation on outcomes of multiple myeloma: A CIBMTR analysis. Journal Of Clinical Oncology 2022, 40: 8057-8057. DOI: 10.1200/jco.2022.40.16_suppl.8057.
• 168 Impact of Post-Remission Consolidation Therapy on Outcomes of Haploidentical Hematopoietic Cell Transplantation for Acute Myelogenous LeukemiaMirza A, Byrne M, Huntington S, Shallis R, Zeidan A, Foss F, Isufi I, Podoltsev N, Engelhardt B, Kassim A, Savani B, Dholaria B, Jayani R, Perrault S, Schiffer M, Seropian S, Gowda L. 168 Impact of Post-Remission Consolidation Therapy on Outcomes of Haploidentical Hematopoietic Cell Transplantation for Acute Myelogenous Leukemia. Transplantation And Cellular Therapy 2022, 28: s139-s140. DOI: 10.1016/s2666-6367(22)00329-3.
• 46 A Multi-Center Collaborative Study of Outcomes of TP53-Mutated MDS/AML Patients Following Allogeneic HCTByrne M, Kurian T, Patel D, Tamari R, Hong S, Abdelhakim H, Klein V, Rojas P, Madhavan R, Kent A, Logan A, Lee C, Husnain M, Manning B, Tschernia N, Dias A, Margalski D, Goldenson B, Byrne N, Chen H, Petrova-Drus K, Sengsayadeth S, Goodman A, Howard D, Wood W, Gill S, Jimenez A, Gutman J, Gowda L, Metheny L, Bhatnagar B, Hamilton B, Mishra A, Savona M. 46 A Multi-Center Collaborative Study of Outcomes of TP53-Mutated MDS/AML Patients Following Allogeneic HCT. Transplantation And Cellular Therapy 2022, 28: s40-s41. DOI: 10.1016/s2666-6367(22)00207-x.
• Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant ResearchMurthy HS, Ahn KW, Estrada-Merly N, Alkhateeb HB, Bal S, Kharfan-Dabaja MA, Dholaria B, Foss F, Gowda L, Jagadeesh D, Sauter C, Abid MB, Aljurf M, Awan FT, Bacher U, Badawy SM, Battiwalla M, Bredeson C, Cerny J, Chhabra S, Deol A, Diaz MA, Farhadfar N, Freytes C, Gajewski J, Gandhi MJ, Ganguly S, Grunwald MR, Halter J, Hashmi S, Hildebrandt GC, Inamoto Y, Jimenez-Jimenez AM, Kalaycio M, Kamble R, Krem MM, Lazarus HM, Lazaryan A, Maakaron J, Munshi PN, Munker R, Nazha A, Nishihori T, Oluwole OO, Ortí G, Pan DC, Patel SS, Pawarode A, Rizzieri D, Saba NS, Savani B, Seo S, Ustun C, van der Poel M, Verdonck LF, Wagner JL, Wirk B, Oran B, Nakamura R, Scott B, Saber W. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplantation And Cellular Therapy 2022, 28: 187.e1-187.e10. PMID: 35081472, PMCID: PMC8977261, DOI: 10.1016/j.jtct.2022.01.017.
• Azacitidine maintenance in AML post induction and posttransplantBewersdorf JP, Prebet T, Gowda L. Azacitidine maintenance in AML post induction and posttransplant. Current Opinion In Hematology 2022, 29: 84-91. PMID: 35013047, DOI: 10.1097/moh.0000000000000700.
• Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AMLMenghrajani K, Gomez-Arteaga A, Madero-Marroquin R, Zhang MJ, Bo-Subait K, Sanchez J, Wang HL, Aljurf M, Assal A, Bacher V, Badawy SM, Bejanyan N, Bhatt VR, Bredeson C, Byrne M, Castillo P, Cerny J, Chhabra S, Ciurea SO, DeFilipp Z, Farhadfar N, Gadalla S, Gale RP, Ganguly S, Gowda L, Grunwald M, Hashmi S, Hildebrandt G, Kanakry CG, Kansagra A, Khimani F, Krem M, Lazarus H, Liu H, Martino R, Michelis FV, Nathan S, Nishihori T, Olsson R, Reshef R, Rizzieri D, Rowe JM, Savani BN, Seo S, Sharma A, Solh M, Ustun C, Verdonck LF, Hourigan C, Sandmaier B, Litzow M, Kebriaei P, Weisdorf D, Zhang Y, Tallman MS, Saber W. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Advances 2022, 6: 828-847. PMID: 34551064, PMCID: PMC8945306, DOI: 10.1182/bloodadvances.2021004881.
• Major ABO Incompatibility Significantly Influences the Survival and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Leukemia - CIBMTR AnalysisMurthy S, Logan B, Bo-Subait S, Beitingjaneh A, Devine S, Farhadfar N, Gowda L, Hashmi S, Lazarus H, Nathan S, Sharma A, Yared J, Stefanski H, Pulsipher M, Hsu J, Switzer G, Panch S, Shaw B. Major ABO Incompatibility Significantly Influences the Survival and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Leukemia - CIBMTR Analysis. Blood 2021, 138: 907. DOI: 10.1182/blood-2021-150635.
• Non-Relapse Mortality in TP53-Mutated MDS/AML - a Multi-Center Collaborative StudyByrne M, Kurian T, Patel D, Tamari R, Hong S, Abdelhakim H, Klein V, Rojas P, Madhavan R, Kent A, Logan A, Lee C, Husnain M, Manning B, Tschernia N, Dias A, Margalski D, Goldenson B, Byrne N, Chen H, Petrova-Drus K, Sengsayadeth S, Goodman A, Howard D, Wood W, Gill S, Jimenez A, Gutman J, Gowda L, Metheny L, Bhatnagar B, Hamilton B, Mishra A, Savona M. Non-Relapse Mortality in TP53-Mutated MDS/AML - a Multi-Center Collaborative Study. Blood 2021, 138: 2922. DOI: 10.1182/blood-2021-154151.
• Life Expectancy After Allogeneic Stem Cell Transplant—In It for the Long Haul?Gowda L, Seropian S. Life Expectancy After Allogeneic Stem Cell Transplant—In It for the Long Haul? JAMA Oncology 2021, 7: 1611-1613. PMID: 34499090, DOI: 10.1001/jamaoncol.2021.3674.
• Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation–A Systematic Review and Meta-AnalysisBewersdorf JP, Allen C, Mirza AS, Grimshaw AA, Giri S, Podoltsev NA, Gowda L, Cho C, Tallman MS, Zeidan AM, Stahl M. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation–A Systematic Review and Meta-Analysis. Transplantation And Cellular Therapy 2021, 27: 997.e1-997.e11. PMID: 34551341, PMCID: PMC9533376, DOI: 10.1016/j.jtct.2021.09.005.
• Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplantBewersdorf JP, Derkach A, Gowda L, Menghrajani K, DeWolf S, Ruiz JD, Ponce DM, Shaffer BC, Tamari R, Young JW, Jakubowski AA, Gyurkocza B, Chan A, Xiao W, Glass J, King AC, Cai SF, Daniyan A, Famulare C, Cuello BM, Podoltsev NA, Roshal M, Giralt S, Perales MA, Seropian S, Cho C, Zeidan AM, Prebet T, Stein EM, Tallman MS, Goldberg AD, Stahl M. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. Leukemia & Lymphoma 2021, 62: 3394-3401. PMID: 34477024, PMCID: PMC9012492, DOI: 10.1080/10428194.2021.1966788.
• Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A. Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia 2021, 35: 2141. PMID: 34091601, DOI: 10.1038/s41375-021-01304-3.
• Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-AnalysisBewersdorf JP, Sheth AH, Vetsa S, Grimshaw A, Giri S, Podoltsev NA, Gowda L, Tamari R, Tallman MS, Rampal RK, Zeidan AM, Stahl M. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis. Transplantation And Cellular Therapy 2021, 27: 873.e1-873.e13. PMID: 34052505, PMCID: PMC8478722, DOI: 10.1016/j.jtct.2021.05.016.
• Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A systematic review and meta-analysis.Bewersdorf J, Sheth A, Vetsa S, Grimshaw A, Giri S, Podoltsev N, Gowda L, Tamari R, Tallman M, Rampal R, Zeidan A, Stahl M. Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A systematic review and meta-analysis. Journal Of Clinical Oncology 2021, 39: 7045-7045. DOI: 10.1200/jco.2021.39.15_suppl.7045.
• Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantationPercival ME, Wang HL, Zhang MJ, Saber W, de Lima M, Litzow M, Kebriaei P, Abdel-Azim H, Adekola K, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bejanyan N, Bhatt V, Byrne M, Cahn JY, Castillo P, Chao N, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Dias A, Diaz MA, Estey E, Farhadfar N, Frangoul HA, Freytes CO, Gale RP, Ganguly S, Gowda L, Grunwald M, Hossain N, Kamble RT, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Krem M, Lazarus HM, Lee JW, Liesveld JL, Lin R, Liu H, McGuirk J, Munker R, Murthy HS, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Passweg JR, Prestidge T, Ringdén O, Rizzieri DA, Rybka WB, Savoie ML, Schultz KR, Seo S, Sharma A, Solh M, Strair R, van der Poel M, Verdonck LF, Yared JA, Weisdorf D, Sandmaier BM. Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation 2021, 56: 2319-2319. PMID: 34017072, PMCID: PMC8450771, DOI: 10.1038/s41409-021-01353-3.
• Screening of blood donors for sickle cell trait using a DNA‐based approach: Frequency in a multiethnic donor populationGowda L, Vege S, Kessler D, Shaz B, Westhoff CM. Screening of blood donors for sickle cell trait using a DNA‐based approach: Frequency in a multiethnic donor population. Transfusion 2021, 61: 2008-2013. PMID: 33929058, DOI: 10.1111/trf.16403.
• Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantationPercival ME, Wang HL, Zhang MJ, Saber W, de Lima M, Litzow M, Kebriaei P, Abdel-Azim H, Adekola K, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bejanyan N, Bhatt V, Byrne M, Cahn JY, Castillo P, Chao N, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Dias A, Diaz MA, Estey E, Farhadfar N, Frangoul HA, Freytes CO, Gale RP, Ganguly S, Gowda L, Grunwald M, Hossain N, Kamble RT, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Krem M, Lazarus HM, Lee JW, Liesveld JL, Lin R, Liu H, McGuirk J, Munker R, Murthy HS, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Passweg JR, Prestidge T, Ringdén O, Rizzieri DA, Rybka WB, Savoie ML, Schultz KR, Seo S, Sharma A, Solh M, Strair R, van der Poel M, Verdonck LF, Yared JA, Weisdorf D, Sandmaier BM. Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation 2021, 56: 2108-2117. PMID: 33864019, PMCID: PMC8425595, DOI: 10.1038/s41409-021-01261-6.
• Breaking the Age Barrier: Physicians’ Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older AdultsMishra A, Preussler JM, Bhatt VR, Bredeson C, Chhabra S, D'Souza A, Dahi PB, Hacker ED, Gowda L, Hashmi SK, Howard DS, Jakubowski A, Jayani R, Koll T, Lin RJ, Olin RL, Popat UR, Rodriguez C, Rosko A, Sabloff M, Sorror ML, Sung AD, Ustun C, Wood WA, Burns L, Artz A. Breaking the Age Barrier: Physicians’ Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults. Transplantation And Cellular Therapy 2021, 27: 617.e1-617.e7. PMID: 33836312, PMCID: PMC8254775, DOI: 10.1016/j.jtct.2021.03.028.
• Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current eraDhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D’Souza A. Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia 2021, 35: 1828-1828. PMID: 33782538, PMCID: PMC8188513, DOI: 10.1038/s41375-021-01233-1.
• 581 The Effect of Cyclophosphamide Pharmacogenomics on Cardiac, Hemorrhagic Cystitis, and Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)Gerstein R, Schiffer M, Perreault S, Gowda L, Foss F, Isufi I, Seropian S. 581 The Effect of Cyclophosphamide Pharmacogenomics on Cardiac, Hemorrhagic Cystitis, and Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH). Transplantation And Cellular Therapy 2021, 27: s466-s467. DOI: 10.1016/s2666-6367(21)00606-0.
• 575 Application of Pharmacogenomic Guided Immunosuppression Dosing in Allogeneic Hematopoietic Stem Cell Transplant (HSCT)Perreault S, Schiffer M, Gowda L, Foss F, Isufi I, Seropian S. 575 Application of Pharmacogenomic Guided Immunosuppression Dosing in Allogeneic Hematopoietic Stem Cell Transplant (HSCT). Transplantation And Cellular Therapy 2021, 27: s461. DOI: 10.1016/s2666-6367(21)00600-x.
• 5 COVID-19 in Hematopoietic Cell Transplant Recipients: A CIBMTR StudySharma A, Bhatt N, St. Martin A, Abid M, Bloomquist J, Chemaly R, Dandoy C, Gauthier J, Gowda L, Perales M, Seropian S, Shaw B, Tuschl E, Zeidan A, Riches M, Shah G. 5 COVID-19 in Hematopoietic Cell Transplant Recipients: A CIBMTR Study. Transplantation And Cellular Therapy 2021, 27: s4-s5. PMCID: PMC7847402, DOI: 10.1016/s2666-6367(21)00031-2.
• Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort studySharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J, Chemaly RF, Dandoy C, Gauthier J, Gowda L, Perales MA, Seropian S, Shaw BE, Tuschl EE, Zeidan AM, Riches ML, Shah GL. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. The Lancet Haematology 2021, 8: e185-e193. PMID: 33482113, PMCID: PMC7816949, DOI: 10.1016/s2352-3026(20)30429-4.
• Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid MalignanciesShallis RM, Bewersdorf JP, Swoboda DM, Wei W, Gowda L, Prebet T, Halene S, Pillai MM, Parker T, Neparidze N, Podoltsev NA, Seropian S, Sallman DA, Gore SD, Zeidan AM. Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies. Clinical Lymphoma Myeloma & Leukemia 2021, 21: e483-e487. PMID: 33551344, DOI: 10.1016/j.clml.2021.01.003.
• 574. De-escalation of Broad Spectrum Antibiotics during Cytokine Release Syndrome with Haploidentical Hematopoietic Stem Cell TransplantationSchiffer M, Perreault S, McManus D, Foss F, Gowda L, Isufi I, Seropian S, Topal J. 574. De-escalation of Broad Spectrum Antibiotics during Cytokine Release Syndrome with Haploidentical Hematopoietic Stem Cell Transplantation. Open Forum Infectious Diseases 2020, 7: s352-s352. PMCID: PMC7776323, DOI: 10.1093/ofid/ofaa439.768.
• 577. Incidence and Outcomes of Positive Outpatient Surveillance Blood Cultures in Hematopoietic Stem Cell Transplant (HSCT) Patients with Graft Versus Host Disease (GvHD) On High Dose ≥ 0.5 mg/kg/day (HD) and Low Dose < 0.5mg/kg/day (LD) Steroid TherapyPerreault S, Schiffer M, Zhao J, McManus D, Foss F, Gowda L, Isufi I, Seropian S, Topal J. 577. Incidence and Outcomes of Positive Outpatient Surveillance Blood Cultures in Hematopoietic Stem Cell Transplant (HSCT) Patients with Graft Versus Host Disease (GvHD) On High Dose ≥ 0.5 mg/kg/day (HD) and Low Dose < 0.5mg/kg/day (LD) Steroid Therapy. Open Forum Infectious Diseases 2020, 7: s353-s354. PMCID: PMC7776791, DOI: 10.1093/ofid/ofaa439.771.
• A case of acute myeloid leukemia with unusual germline CEBPA mutation: lessons learned about mutation detection, location, and penetranceMendoza H, Chen PH, Pine AB, Siddon AJ, Bale AE, Gowda L, Killie A, Richards J, Varin-Tremblay C, Kloss R, Podoltsev NA. A case of acute myeloid leukemia with unusual germline CEBPA mutation: lessons learned about mutation detection, location, and penetrance. Leukemia & Lymphoma 2020, 62: 1251-1254. PMID: 33345654, DOI: 10.1080/10428194.2020.1861276.
• Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell LymphomasLee M, Schiffer M, Isufi I, Huntington S, Xu M, Seropian S, Gowda L, Kothari S, Girardi M, Foss F. Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas. Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-139790.
• Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTRMurthy H, Ahn K, Estrada-Merly N, Gowda L, Dholaria B, Bal S, Alkhateeb H, Jagadeesh D, Oran B, Nakamura R, Scott B, Sauter C, Foss F, kharfan-Dabaja M, Saber W. Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR. Blood 2020, 136: 28-29. DOI: 10.1182/blood-2020-134793.
• Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomasIsufi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M, Perreault S, Foss F. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. Leukemia & Lymphoma 2020, 61: 2955-2961. PMID: 32643494, DOI: 10.1080/10428194.2020.1790555.
• Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on RuxolitinibFoss FM, Rubinowitz A, Landry ML, Isufi I, Gowda L, Seropian S, Perreault S, Shenoi SV. Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib. Clinical Lymphoma Myeloma & Leukemia 2020, 20: 720-723. PMID: 32727701, PMCID: PMC7316063, DOI: 10.1016/j.clml.2020.06.014.
• Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*Bewersdorf JP, Shallis RM, Gowda L, Wei W, Hager K, Isufi I, Kim TK, Pillai MM, Seropian S, Podoltsev NA, Gore SD, Siddon AJ, Zeidan AM. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*. Leukemia & Lymphoma 2020, 61: 2180-2190. PMID: 32362171, PMCID: PMC7603787, DOI: 10.1080/10428194.2020.1759051.
• Isolated trisomy 11 in patients with acute myeloid leukemia – is the prognosis not as grim as previously thought?*Bewersdorf JP, Shallis RM, Diadamo A, Gowda L, Podoltsev NA, Siddon A, Zeidan AM. Isolated trisomy 11 in patients with acute myeloid leukemia – is the prognosis not as grim as previously thought?*. Leukemia & Lymphoma 2020, 61: 2254-2257. PMID: 32338096, PMCID: PMC7485109, DOI: 10.1080/10428194.2020.1755858.
• Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current eraDhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D’Souza A. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia 2020, 34: 3338-3347. PMID: 32313109, PMCID: PMC7572530, DOI: 10.1038/s41375-020-0830-0.
• Cui bono? Finding the value of allogeneic stem cell transplantation for lower-risk myelodysplastic syndromesShallis RM, Podoltsev NA, Gowda L, Zeidan AM, Gore SD. Cui bono? Finding the value of allogeneic stem cell transplantation for lower-risk myelodysplastic syndromes. Expert Review Of Hematology 2020, 13: 447-460. PMID: 32182435, DOI: 10.1080/17474086.2020.1744433.
• Investigation of increased platelet alloimmunization screening in the era of pathogen‐reduced platelets treated with psoralen/UV lightHendrickson JE, Mendoza H, Ross R, Siddon AJ, Gowda L, Hauser RG, Schulz WL, Tormey CA. Investigation of increased platelet alloimmunization screening in the era of pathogen‐reduced platelets treated with psoralen/UV light. Transfusion 2020, 60: 650-651. PMID: 32128834, DOI: 10.1111/trf.15691.
• Predictive Value of PET-CT in Patients with T-Cell Lymphoma Undergoing Autologous and Allogeneic Stem Cell TransplantIsufi I, Chandhok N, Boddu P, Pucar D, Seropian S, Gowda L, Perreault S, Wilson L, Roberts K, Foss F. Predictive Value of PET-CT in Patients with T-Cell Lymphoma Undergoing Autologous and Allogeneic Stem Cell Transplant. Transplantation And Cellular Therapy 2020, 26: s244. DOI: 10.1016/j.bbmt.2019.12.492.
• Transplant Physicians’ Attitudes on Candidacy for Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Patients: The Need for a Standardized Geriatric Assessment (GA) ToolMishra A, Preussler J, Al-Mansour Z, Bachanova V, Bhatt V, Bredeson C, Chhabra S, D'Souza A, Dahi P, DeFilipp Z, Gowda L, Hacker E, Hashmi S, Howard D, Jakubowski A, Jayani R, Johnston L, Koll T, Lin R, McCurdy S, Michaelis L, Muffly L, Nathwani N, Olin R, Popat U, Rodriguez C, Rosko A, Runaas L, Sabloff M, Shore T, Shune L, Sorror M, Sung A, Ustun C, Wood W, Burns L, Artz A. Transplant Physicians’ Attitudes on Candidacy for Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Patients: The Need for a Standardized Geriatric Assessment (GA) Tool. Transplantation And Cellular Therapy 2020, 26: s45-s46. DOI: 10.1016/j.bbmt.2019.12.115.
• Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center ExperienceBewersdorf J, Shallis R, Gowda L, Hager K, Podoltsev N, Gore S, Prebet T, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Siddon A, Zeidan A. Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center Experience. Blood 2019, 134: 5173. DOI: 10.1182/blood-2019-127162.
• Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought?Bewersdorf J, Shallis R, Diadamo A, Gowda L, Podoltsev N, Gore S, Prebet T, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Siddon A, Zeidan A. Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought? Blood 2019, 134: 5174. DOI: 10.1182/blood-2019-127277.
• Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center ExperienceShallis R, Bewersdorf J, Gowda L, Podoltsev N, Prebet T, Gore S, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Zeidan A. Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience. Blood 2019, 134: 1330. DOI: 10.1182/blood-2019-127422.
• Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell TransplantationChandhok N, Huntington S, Isufi I, Gowda L, Xu M, Bar N, Seropian S, Foss F. Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation. Blood 2019, 134: 4055. DOI: 10.1182/blood-2019-128888.
• Primary Plasma Cell Leukemia Outcomes Remain Dismal Despite Novel Agents and Hematopoietic Cell TransplantationPatel S, Girnius S, Dhakal B, Gowda L, Fraser R, Davila O, Shah N, Qazilbash M, Kumar S, D'Souza A, Hari P. Primary Plasma Cell Leukemia Outcomes Remain Dismal Despite Novel Agents and Hematopoietic Cell Transplantation. Blood 2019, 134: 266. DOI: 10.1182/blood-2019-127049.
• Hyperleukocytosis in Cancer PatientsGowda L, Hosing C. Hyperleukocytosis in Cancer Patients. 2019, 1147-1153. DOI: 10.1007/978-3-319-74588-6_94.
• Hyperleukocytosis in Cancer PatientsGowda L, Hosing C. Hyperleukocytosis in Cancer Patients. 2019, 1-7. DOI: 10.1007/978-3-319-74698-2_94-1.
• Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerationsShallis RM, Gleeson S, Azar M, Malinis M, Xu ML, Seropian SE, Gowda L, Zeidan AM. Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations. Leukemia & Lymphoma 2019, 60: 2584-2587. PMID: 30943051, DOI: 10.1080/10428194.2019.1594221.
• Allogeneic Stem Cell Transplantation for T-Cell Lymphomas in the Modern Era: A Single Center ExperienceBoddu P, Perreault S, Isufi I, Chandhok N, Kim T, Pillai M, Bar N, Prebet T, Zeidan A, Zelterman D, Seropian S, Gowda L, Foss F. Allogeneic Stem Cell Transplantation for T-Cell Lymphomas in the Modern Era: A Single Center Experience. Transplantation And Cellular Therapy 2019, 25: s387. DOI: 10.1016/j.bbmt.2018.12.796.
• Restrictive Transfusions in the Era of Pathogen-Inactivated Platelets: A Single Center ExperienceShallis R, Gleeson S, Chokr N, Fangyong L, Wei W, Azar M, Schulz W, Summers D, Hendrickson J, Foss F, Isufi I, Kim T, Pillai M, Snyder E, Seropian S, Gowda L. Restrictive Transfusions in the Era of Pathogen-Inactivated Platelets: A Single Center Experience. Transplantation And Cellular Therapy 2019, 25: s365. DOI: 10.1016/j.bbmt.2018.12.591.
• The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN)Perreault S, McManus D, Bar N, Foss F, Gowda L, Isufi I, Seropian S, Malinis M, Topal JE. The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN). Transplant Infectious Disease 2019, 21: e13059. PMID: 30737868, DOI: 10.1111/tid.13059.
• HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplantGhobadi A, Milton DR, Gowda L, Rondon G, Chemaly RF, Hamdi A, Alousi A, Afrough A, Oran B, Ciurea S, Kebriaei P, Popat UR, Qazilbash MH, Shpall EJ, Champlin RE, Bashir Q. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. Current Research In Translational Medicine 2019, 67: 51-55. PMID: 30683577, PMCID: PMC7735254, DOI: 10.1016/j.retram.2019.01.001.
• Hepatosplenic T-Cell LymphomasGowda L, Foss F. Hepatosplenic T-Cell Lymphomas. 2018, 176: 185-193. PMID: 30596219, DOI: 10.1007/978-3-319-99716-2_9.
• A dual strategy to optimize hematopoietic progenitor cell collections: validation of a simple prediction algorithm and use of collect flow rates guided by mononuclear cell countGodbey EA, Dormesy S, Gowda L, Nandi V, Paradiso S, Sachais BS, Shi PA. A dual strategy to optimize hematopoietic progenitor cell collections: validation of a simple prediction algorithm and use of collect flow rates guided by mononuclear cell count. Transfusion 2018, 59: 659-670. PMID: 30537213, DOI: 10.1111/trf.15034.
• Sensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation.Shah MV, Patel KP, Luthra R, Kanagal-Shamanna R, Mehrotra M, Bachegowda LS, Champlin RE, Verstovsek S, Popat UR. Sensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation. British Journal Of Haematology 2018, 183: 831-835. PMID: 29265180, DOI: 10.1111/bjh.15059.
• Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugsGowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, Manasanch EE, Shah A, Thomas SK, Parmar S, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplantation 2018, 54: 1089-1093. PMID: 30446740, PMCID: PMC8393277, DOI: 10.1038/s41409-018-0392-1.
• CAR‐T cell manufacture: snatching victory when defeat is loomingGowda L, Shah NC. CAR‐T cell manufacture: snatching victory when defeat is looming. Transfusion 2018, 58: 1335-1337. PMID: 29949188, DOI: 10.1111/trf.14760.
• 341 Primary Plasma Cell Leukemia: Stem Cell Transplant in an Era of Novel Induction DrugsGowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta R, Weber D, Lee H, Manasanch E, Shah A, Thomas S, Parmar S, Nieto Y, Orlowski R, Champlin R, Qazilbash M. 341 Primary Plasma Cell Leukemia: Stem Cell Transplant in an Era of Novel Induction Drugs. Transplantation And Cellular Therapy 2018, 24: s260-s261. DOI: 10.1016/j.bbmt.2017.12.239.
• Survey on Transfusion-Transmitted Cytomegalovirus and Cytomegalovirus Disease Mitigation.Weisberg SP, Staley EM, Williams LA, Pham HP, Bachegowda LS, Cheng YH, Schwartz J, Shaz BH. Survey on Transfusion-Transmitted Cytomegalovirus and Cytomegalovirus Disease Mitigation. Archives Of Pathology & Laboratory Medicine 2017, 141: 1705-1711. PMID: 28849943, DOI: 10.5858/arpa.2016-0461-OA.
• Impact of predictive scoring model and e-mail messages on African American blood donors.Bachegowda LS, Timm B, Dasgupta P, Hillyer CD, Kessler D, Rebosa M, France CR, Shaz BH. Impact of predictive scoring model and e-mail messages on African American blood donors. Transfusion 2017, 57: 1515-1521. PMID: 28474337, DOI: 10.1111/trf.14113.
• Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation.Bachegowda LS, Saliba RM, Ramlal R, Kongtim P, Chen J, Rondon G, Wallis W, Alousi A, Ahmed S, Hosing CM, Parmar S, Qazilbash M, Khouri IF, Bashir Q, Oran B, Popat U, Shpall EJ, Marin D, Rezvani K, Kebriaei P, Champlin RE, Ciurea SO. Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. Blood 2017, 129: 3031-3033. PMID: 28351938, PMCID: PMC6033074, DOI: 10.1182/blood-2017-02-766154.
• Impact of Uniform Methods on Interlaboratory Antibody Titration Variability: Antibody Titration and Uniform Methods.Bachegowda LS, Cheng YH, Long T, Shaz BH. Impact of Uniform Methods on Interlaboratory Antibody Titration Variability: Antibody Titration and Uniform Methods. Archives Of Pathology & Laboratory Medicine 2017, 141: 131-138. PMID: 27681333, DOI: 10.5858/arpa.2015-0351-OA.
• Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.Bachegowda L, Morrone K, Winski SL, Mantzaris I, Bartenstein M, Ramachandra N, Giricz O, Sukrithan V, Nwankwo G, Shahnaz S, Bhagat T, Bhattacharyya S, Assal A, Shastri A, Gordon-Mitchell S, Pellagatti A, Boultwood J, Schinke C, Yu Y, Guha C, Rizzi J, Garrus J, Brown S, Wollenberg L, Hogeland G, Wright D, Munson M, Rodriguez M, Gross S, Chantry D, Zou Y, Platanias L, Burgess LE, Pradhan K, Steidl U, Verma A. Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia. Cancer Research 2016, 76: 4841-4849. PMID: 27287719, PMCID: PMC5398415, DOI: 10.1158/0008-5472.CAN-15-3062.
• Engraftment for CD34 selected stem cell products is not compromised by cryopreservation.Reich-Slotky R, Bachegowda LS, Ancharski M, Gergis U, van Besien K, Cushing MM. Engraftment for CD34 selected stem cell products is not compromised by cryopreservation. Transfusion 2016, 56: 893-8. PMID: 26661996, DOI: 10.1111/trf.13435.
• How we handled the dextran shortage: an alternative washing or dilution solution for cord blood infusions.Reich-Slotky R, Bachegowda LS, Ancharski M, Mendeleyeva L, Rubinstein P, Rennert H, Shore T, van Besien K, Cushing M. How we handled the dextran shortage: an alternative washing or dilution solution for cord blood infusions. Transfusion 2015, 55: 1147-53. PMID: 25652820, DOI: 10.1111/trf.13015.
• Genetic and molecular targets in lymphoma: implications for prognosis and treatment.Bachegowda LS, Barta SK. Genetic and molecular targets in lymphoma: implications for prognosis and treatment. Future Oncology (London, England) 2014, 10: 2509-28. PMID: 25525858, DOI: 10.2217/fon.14.112.
• Taxanes: impact on breast cancer therapy.Bachegowda LS, Makower DF, Sparano JA. Taxanes: impact on breast cancer therapy. Anti-cancer Drugs 2014, 25: 512-21. PMID: 24552749, DOI: 10.1097/CAD.0000000000000090.
• Signal transduction inhibitors in treatment of myelodysplastic syndromes.Bachegowda L, Gligich O, Mantzaris I, Schinke C, Wyville D, Carrillo T, Braunschweig I, Steidl U, Verma A. Signal transduction inhibitors in treatment of myelodysplastic syndromes. Journal Of Hematology & Oncology 2013, 6: 50. PMID: 23841999, PMCID: PMC3716523, DOI: 10.1186/1756-8722-6-50.
• Changes in intern attitudes toward medical error and disclosure.Varjavand N, Bachegowda LS, Gracely E, Novack DH. Changes in intern attitudes toward medical error and disclosure. Medical Education 2012, 46: 668-77. PMID: 22691146, DOI: 10.1111/j.1365-2923.2012.04269.x.
• Intracranial tumor lysis and cerebral edema after administration of intrathecal methotrexate: a case report and discussion.Bachegowda LS, Grivas PD, Anand R, Stecker E, Ward K. Intracranial tumor lysis and cerebral edema after administration of intrathecal methotrexate: a case report and discussion. Medical Oncology (Northwood, London, England) 2010, 27: 1079-81. PMID: 19847678, DOI: 10.1007/s12032-009-9338-1.
• Role of plasmapheresis in the management of myeloma kidney: a systematic review.Gupta D, Bachegowda L, Phadke G, Boren S, Johnson D, Misra M. Role of plasmapheresis in the management of myeloma kidney: a systematic review. Hemodialysis International. International Symposium On Home Hemodialysis 2010, 14: 355-63. PMID: 20955270, DOI: 10.1111/j.1542-4758.2010.00481.x.
• Granuloma annulare.Gupta D, Hess B, Bachegowda L. Granuloma annulare. TheScientificWorldJournal 2010, 10: 384-6. PMID: 20209383, PMCID: PMC5763746, DOI: 10.1100/tsw.2010.51.